To the relief of clinical laboratory and pathology groups, the FDA user fee reauthorization bill (S. 1082) that the Senate HELP Committee approved April 18 did not include controversial provisions requiring premarket review of lab-developed tests (LDTs).

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

April 23, 2007 - Table of Contents

NIR April 23, 2007 (full PDF issue)

CMS Discloses More Details on NPI Compliance Policy

Industry Dodges the Bullet, for Now, on Lab-Developed Tests

CMS Gears Up for New Medicare Quality Reporting Program

Congressional Scorecard on Major Pending Bills

CMS Updates Lab Coalition on Medicare Bidding Demo

Follow-Up on the ‘Lab Lobbying Blitz’